Introduction {#Sec1}
============

Adenosine 5′-triphosphate-sensitive K^+^ (K~ATP~) channel openers have been used in clinical trials for the treatment of hypertension and asthma. The most common side effect mentioned during treatment with K~ATP~ channel openers was headache (62, 64, 66--79) (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). However, only little attention has been focused on the role of K~ATP~ channels in migraine pathophysiology.

K~ATP~ channels were originally identified in cardiomyocytes \[[@CR1]\], but have also been found in several tissues, including pancreatic α- and ß-cells, smooth muscle, skeletal muscle and central neurons \[[@CR2], [@CR3]\]. The channels belong to the family of inwardly rectifying K^+^ channels that are inhibited at physiological intracellular levels ATP/ADP ratio. When intracellular ATP is reduced under conditions of metabolic challenges they open. K~ATP~ channels are critical in regulating insulin secretion, controlling vascular tone, and protecting cells against metabolic stress \[[@CR2], [@CR4], [@CR5]\].

Over the past three decades, some preclinical evidence has emerged indicating that K~ATP~ channels may play an important role in migraine pathophysiology. In particular, the vasodilation effect of K~ATP~ channels is relevant, since it is has been established that endogenous neurotransmitters that trigger migraine attacks are often associated with dilation of cranial arteries \[[@CR6]\].

Here we review preclinical and clinical studies on K~ATP~ channels and discuss the K~ATP~ channel as a novel therapeutic target for migraine treatment.

Molecular structure and isoforms {#Sec2}
================================

The K~ATP~ channel is a hetero-octameric complex that consists of four pore-forming K^+^ inwardly rectifying (Kir) subunits and four regulatory sulfonylurea receptor (SUR) subunits \[[@CR7]\].

The Kir6.x subunit exists in two isoforms, Kir6.1 and Kir6.2. The SUR subunit belongs to the ATP-binding cassette (ABC) transporter family, regulated by sulfonylurea, with three isoforms, SUR1, SUR2A, and SUR2B \[[@CR7], [@CR8]\].

K~ATP~channels have specific tissue expression with different compositions of Kir6.x and SUR subunits which lead to distinct functional properties (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}).Fig. 1Molecular structure and isoforms. **a** Two major Kir6.x isoforms (Kir6.1 and Kir 6.2) and three major SUR isoforms (SUR1, SUR2A and SUR 2B) have been identified. **b** Kir.x subunits combine tissue-specifically with different SUR subunits to form various native K~ATP~ channels. Pancreatic, cardiac and smooth muscle K~ATP~ channels are made up of Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.1 (or Kir6.2)/SUR2B, respectively \[[@CR2]\]. Kir, inwardly rectifying K^+^ channels; SUR, sulfonylurea receptor Fig. 2Schematic diagram of the K~ATP~ channel. Kir6.x subunits have two transmembrane domains, and a large cytoplasmic domain including an inhibitory binding site for ATP \[[@CR8], [@CR84]\]. SUR subunits have many transmembrane domains and two intracellular nucleotide binding domains (NBD1 and NBD2), which stimulate opening of the channel after binding to MgADP \[[@CR85]\] Table 1Distribution of K~ATP~ channelsSubtypes of K~ATP~channelsTissue expressionMigraine related structuresKir6.2/SUR1Pancreas and brainDRG, TG and TNC from rats (20--24, 26).Kir6.2/SUR2ACardiac and skeletal muscleKir6.2/SUR2BSmooth muscleDRG, TG, TNC, BA and MCA from rats(20--24, 26).Kir6.1/SUR2BSmooth muscleMMA from rats, pigs and human; MCA from rats and pigs; BA, DRG, TG and TNC from rats (20--24, 26).*DRG* Dorsal root ganglia, *TG* trigeminal ganglion, *TNC* trigeminal nucleus caudatus, *BA* basilar artery, *MMA* middle meningeal artery, *MCA* middle cerebral artery

Channel function {#Sec3}
================

K~ATP~ channel activity is controlled by changes in concentrations of intracellular ATP and magnesium adenosine diphosphate (Mg-ADP). K~ATP~ channels couple the metabolic state of the cell to the membrane potential and thus play a crucial role in many tissues under both physiological and pathological conditions \[[@CR9]\]. K^+^ channels participate in the regulation of vascular tone, including cerebral arteries \[[@CR10]\]. When intracellular ATP is reduced, K~ATP~ channels become activated; K^+^ efflux hyperpolarize the membrane and close voltage-operated Ca^2+^-channels (VOCC). The result is a decrease in cytosolic Ca^2+^ concentration followed by relaxation of vascular smooth muscle cells and an increase in blood flow \[[@CR11]\]. The same applies if cells are exposed to metabolic stress such as ischemia or hypoglycemia \[[@CR12]\]. Closure of K^+^ channels leads to membrane depolarization and constriction of the vessels \[[@CR11]\]. In addition an increase in intracellular cAMP and cGMP levels activate K~ATP~ channels to produce vasodilation \[[@CR11]\]. Synthetic K~ATP~ channel openers (like levcromakalim and cromakalim) and blockers (like glibenclamide, second generation of sulfonylurea and PNU37883A) directly activate or inhibit the vascular K~ATP~ channels, respectively \[[@CR9]\] (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Opening of vascular ATP sensitive K channels. Endogenous molecules (ATP, cAMP and cGMP) and exogenous pharmacological agents (cromakalim and glibenclamide) regulate the activity of K~ATP~ channels, which help controlling the vascular tone

Distribution of K~ATP~ channels in migraine related structures {#Sec4}
==============================================================

Intracranial arteries {#Sec5}
---------------------

K~ATP~ channels are present and functional in intracranial arteries \[[@CR13]--[@CR15]\]. They are found in vascular smooth muscle cells and vascular endothelial cells \[[@CR16], [@CR17]\]. In rat cerebral arteries, the distribution of K~ATP~ channels varies with vessel size and brain region \[[@CR18]\]. Real time polymerase chain reaction (RT-PCR) analysis revealed Kir6.1 and SUR2B subunits in middle meningeal artery (MMA) and middle cerebral artery (MCA) in rats and pigs \[[@CR19], [@CR20]\]. This profile of K~ATP~ channels is also identified in human MMA \[[@CR21]\] (Table [1](#Tab1){ref-type="table"}).

Trigeminal ganglion and trigeminal nucleus caudalis {#Sec6}
---------------------------------------------------

Kir6.1, Kir6.2, SUR1 and SUR2 are expressed in the trigeminal ganglion and trigeminal nucleus caudalis \[[@CR22]\] (Table [1](#Tab1){ref-type="table"}). In trigeminal neurons Kir 6.1 and Kir 6.2 immunoreactivity were expressed in cells with all soma sizes in all three divisions of the trigeminal ganglion \[[@CR23]\].

K~ATP~ channels openers and migraine signaling pathways {#Sec7}
=======================================================

A number of endogenous vasoactive signaling molecules have been implicated in migraine \[[@CR6]\], and K~ATP~ channels may interact with these molecules.

Nitric oxide (NO) {#Sec8}
-----------------

In humans, infusion of the NO donor, glyceryl trinitrate, and inhibition of the breakdown of cGMP by sildenafil \[[@CR24]\] provoke migraine attacks in migraineurs \[[@CR25]--[@CR27]\]. The NO-cGMP signaling pathway is involved in the relaxation of vascular smooth muscle \[[@CR28]\]. In vitro studies with cerebral arteries isolated from rat and piglet and extra-cerebral arteries from rabbit reported that activation (opening) of K~ATP~ channels contributed to both cAMP- and cGMP-mediated vasodilation \[[@CR29]--[@CR31]\]. Yuan et al. \[[@CR32]\] reported that sildenafil-induced vasodilation in porcine retinal arterioles was significantly inhibited by glibenclamide and suggested that cGMP signaling triggers opening of K~ATP~ channels. In contrast, NO-induced dural and pial artery dilation in rats was not attenuated by the K~ATP~ channel blocker, glibenclamide \[[@CR33]\]. Together, these data suggest that interspecies differences are likely to explain the discrepancy in findings of the role of K~ATP~ channels in NO-induced vasodilation.

Calcitonin gene-related peptide (CGRP) {#Sec9}
--------------------------------------

CGRP is one of the most potent endogenous vasodilators and major arteries in the intracranial circulation of man and animals are innervated by CGRP-containing nerve fibers \[[@CR34]--[@CR36]\]. Efficacy of CGRP antagonism is established in acute \[[@CR37], [@CR38]\] and preventive treatment of migraine \[[@CR39]\]. CGRP activates vascular smooth muscle K~ATP~ channels indirectly through adenylate cyclase and protein kinase A (PKA) phosphorylation (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR40]--[@CR43]\]. In rats, CGRP-induced dilation of the dural and pial arteries in vivo was shown to be inhibited by glibenclamide \[[@CR33]\], but K~ATP~ channel openers do not interact with CGRP release in trigeminal ganglion and trigeminal nucleus caudalis \[[@CR22]\]. This suggests that K~ATP~ channels are involved in CGRP-induced intracranial vasodilation.Fig. 4Signaling pathways through vascular smooth muscle K~ATP~ channels. Numerous endogenous vasodilators activate vascular smooth muscle K~ATP~ channels through adenylate cyclase and PKA phosphorylation. Conversely, endogenous vasoconstrictors inhibit vascular smooth muscle K~ATP~ channels through DAG and PKC phosphorylation. CGRP, calcitonin gene-related peptide; PGI~2~, prostaglandin I~2~; VIP, vasoactive intestinal peptide; AngII, angiotensin II; NPY, neuropeptide Y; NA, noradrenaline; 5-HT, 5-hydroxytryptamine; Gs, G-protein-coupled receptor alpha stimulation; Gi, G-protein-coupled receptor alpha i/q; DAG, diacylglycerol; PKA and PKC, protein kinase A and C, respectively

Pituitary adenylate cyclase activating polypeptide (PACAP) {#Sec10}
----------------------------------------------------------

Pituitary adenylate cyclase activating polypeptide (PACAP) is a potent endothelium independent vasodilator of various vascular beds, including cerebral arteries \[[@CR44], [@CR45]\]. In vivo and in vitro studies have demonstrated that PACAP dilates cranial arteries in different species, e.g. human cerebral arteries \[[@CR34], [@CR46], [@CR47]\], pig pia artery, canine basilar artery, cat cerebral arteries, rabbit posterior cerebral arteries and rat middle cerebral arteries \[[@CR48]--[@CR52]\]. Emerging data suggest that PACAP or it receptors are a promising target for migraine therapeutics \[[@CR53]\]. PACAP has three types of receptors; Pituitary adenylate cyclase PAC~1~ (*p*ituitary *a*denylate *c*yclase receptor 1), VPAC~1~ (*v*asoactive intestinal peptide and *p*ituitary *a*denylate *c*yclase receptor 1) and VPAC~2~ (*v*asoactive intestinal peptide and *p*ituitary *a*denylate *c*yclase receptor 2) \[[@CR54]\] the two latter ones are also activated by vasoactive intestinal peptide and all three receptors are found in cerebral artery smooth muscle cells \[[@CR55]\]. Through these receptors, PACAP leads to an increase in intracellular cAMP, which activates PKA and produces vasodilation by several mechanisms including activation of K~ATP~ channels (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR45]\]. Interestingly, glibenclamide could partially inhibit PACAP induced vasodilation in cerebral, coronary and pulmonary arteries, suggesting that PACAP may also activate K~ATP~ channels \[[@CR44], [@CR45]\].

Prostaglandins {#Sec11}
--------------

Prostacyclin (PGI~2~) activates and sensitizes meningeal sensory afferents, and provokes immediate migraine-like attacks in migraine sufferers \[[@CR56]\]. PGI~2~ also increases K~ATP~ channel activity in vascular smooth muscle preparations by cAMP-dependent PKA activation \[[@CR57]\] (Fig. [4](#Fig4){ref-type="fig"}).

Headache induced by K~ATP~ channels openers {#Sec12}
===========================================

In the late 80's there was a tremendous interest in developing novel K~ATP~ channel openers for hypertension, angina pectoris and asthma. Three pharmacological drugs were developed, pinacidil, nicorandil and levcromakalim. One of most common adverse events after treatment reported in these studies was headache \[[@CR58]--[@CR63]\].

Six clinical trials with pinacidil have been published for treatment of essential hypertension. Between 7% and 21% of the patients reported headache as an adverse effect (Table [2](#Tab2){ref-type="table"}).Table 2Headache incidences registered during randomized controlled trials (RCT) and open label clinical trials with pinacidilPaperStudy designDose (daily)IndicationNo. of patientsHeadache No.Muiesan et al. 1985, Eur. J. Clin. Pharmacol \[[@CR86]\].RCT30--75 mgEssential hypertension302 (7%)Laher & Hickey 1985, J. Int. Med. Res \[[@CR87]\].Open label12.5 mgHealthy volunteers121 (8%)D'Arcy et al. 1985, Eur. J. Clin. Pharmacol \[[@CR88]\].Open label20--100 mgEssential hypertension234 (17%)Zachariah et al. 1986, Eur. J. Clin. Pharmacol \[[@CR89]\].RCT62 mg (mean)Essential hypertension23\-\-\--Sterndorff & Johansen 1988, Acta Med. Scand \[[@CR90]\].RCT25--100 mgEssential hypertension717 (10%)Goldberg 1988, J. Cardiovasc. Pharmacol \[[@CR91]\].RCT25--100 mgEssential hypertension14531 (21%)

Nicorandil was tested for the treatment of angina pectoris and ischemic heart disease. 23% to 88% of the patients reported headache as an adverse event (Table [3](#Tab3){ref-type="table"}). The high incidence of headache is likely due to the mixed K~ATP~ channel opener and NO donor properties of nicorandil which thus cause vasodilation via two separate mechanisms.Table 3Headache incidences registered during randomized controlled trials (RCT) and open label clinical trials with nicorandilPaperStudy designDose (daily)IndicationNo. of patientsHeadache No.Camm & Maltz, 1989, Am. J. Cardiol \[[@CR92]\].RCT20--60 mgAngina pectoris820 mg 50%\
40 mg 88%\
60 mg 67%Raftery et al. 1993, Eur. Heart Journal \[[@CR93]\].RCT20 mg and 40 mgAngina pectoris1811 (61%)Roland 1993, Eur. Heart Journal \[[@CR94]\].Review10--80 mgAngina pectoris168036%Wolf et al. 1993, Eur.J.Clin.Pharmacol \[[@CR95]\].RCT20--200 μg i.v.Healthy volunteers4819 (40%)Witchitz & Darmaon, 1995, Cardiovasc. Drugs& Therap \[[@CR96]\].Open label20--40 mgAngina pectoris19745 (23%)Dunn et al. 1999, Pharmacoepidemiology and Drug safety \[[@CR97]\].Prescription-event monitoring (PEM) studyVaryingAngina pectoris & ischemic heart disease13,260477 (4%)

Levcromakalim was investigated for the treatment of asthma and essential hypertension. In these studies between 29% and 76% of the patients reported headache as an adverse event (Table [4](#Tab4){ref-type="table"}).Table 4Headache incidences registered during randomized controlled trials (RCT) and open label clinical trials with levcromakalimPaperStudy designDose (daily)IndicationNo. of patientsHeadache No.Singer et al. 1989, J. Hypertens \[[@CR98]\].RCT1.5 mgEssential hypertension84 (50%)Williams et al. 1990, Lancet \[[@CR60]\].RCT1.5 mgAsthma1610 (62%)Kidney et al. 1993, Thorax \[[@CR62]\].RCT0.125--0.5 mgAsthma2519 (76%)Suzuki et al. 1995, Arzneim.-Forsch./Drug Res \[[@CR99]\].Open label0.5--1.0 mgEssential hypertension144 (29%)

The selective synthetic K~ATP~ channel openers levcromakalim and pinacidil have been shown to induce dilation in rat cranial arteries \[[@CR13], [@CR15], [@CR19]\] and in isolated human cerebral arteries \[[@CR64]\]. Moreover, the arterial dilation can be inhibited by synthetic K~ATP~ channel blockers like glibenclamide \[[@CR10], [@CR33]\] and PNU37883A \[[@CR21], [@CR65]\] (Fig. [3](#Fig3){ref-type="fig"}). These findings suggest that high incidences of headache could be due to vasoactive effect of the K~ATP~ channel openers in pain-sensitive extra- and/or intracerebral arteries.

Discussion and future perspectives {#Sec13}
==================================

K~ATP~channels are expressed in migraine-related structures such as the cranial arteries, TG and TNC \[[@CR18]--[@CR22], [@CR66]\]. K~ATP~ channels are also connected to a number of key molecules in migraine pathogenesis, particularly nitric oxide, CGRP, PACAP and PGI~2~ known to provoke migraine attacks \[[@CR56], [@CR67]--[@CR71]\]. Therefore, the K~ATP~ channels are interesting in migraine context.

Human experimental models have demonstrated that the activation of the cAMP and cGMP pathways can trigger headache in healthy volunteers and migraine attacks in migraine sufferers \[[@CR6], [@CR71], [@CR72]\]. The cAMP and cGMP signaling pathways are crucial in the activation of K~ATP~ channels, which result in the relaxation of smooth muscle \[[@CR29]--[@CR31]\]. Furthermore, synthetic K~ATP~ channel openers like levcromakalim and pinacidil trigger headache in non-migraine patients \[[@CR58]--[@CR63]\]. Although a detailed description of levcromakalim- and pinacidil-induced headache and accompanying symptoms are lacking, these data support a role of K~ATP~ channels in migraine headache. Because K~ATP~ channel openers were tested for other indications, there are no available data on the potential migraine-inducing effects of pinacidil and levcromakalim in migraine patients. It is conceivable that both headache and migraine are underreported as adverse events, as was found for the phosphodiesterase inhibitors, cilostazol and sildenafil \[[@CR73], [@CR74]\].

In addition to the vasoactive effects, the K~ATP~ channels might also tap into other parts of the migraine cascade. For a number of patients, migraine attacks are associated with transient focal neurological symptoms called the aura \[[@CR75]\], possibly caused by cortical spread depression (CSD) \[[@CR76]\]. During CSD K^+^ conductance is increased, and CSD may be inhibited by Kir antagonist \[[@CR77]\]. The fact that K~ATP~ channels open under cellular stress, as seen during long lasting depolarizations, could provide a link between K~ATP~ channels, CSD and migraine aura.

With regard to the migraine pain, it is worth noting that K~ATP~ channels are also found in peripheral nociceptive fibers \[[@CR78]\] and activation of these channels play a crucial role in anti-nociception at both spinal and supra-spinal levels \[[@CR23], [@CR79]\]. The exact role of these findings in the headache induced by K~ATP~ channel openers is unknown.

If K~ATP~ channel openers are in fact able to trigger migraine, the next step to consider is whether K~ATP~ channel antagonists can relieve migraine. K~ATP~ blockers for the treatment of migraine should be selective for the Kir6.1/SUR2B subtype because of its dominant presence in vascular tissue (Table [1](#Tab1){ref-type="table"}). The necessity of a subtype specific blocker is unavoidable because of occurrence of different subtypes in different tissues. Glibenclamide cannot be used due to its high affinity to the Kir6.2/SUR1 subtype of K~ATP~ channels present in the pancreas with hypoglycemia as a side effect \[[@CR80]\]. PNU-37883A is a Kir6.1 selective K~ATP~ channel blocker that was originally developed as a diuretic drug \[[@CR81], [@CR82]\]. The drug was not approved to human studies because of its cardiac depressant activity in animal studies \[[@CR83]\]. This precludes further clinical development of PNU-37883A due to possible serious adverse events but may not exclude further investigations in other blockers against Kir6.1 subunit because it is not clear if all blockers against Kir6.1 subunit have non-favorable effects. These findings indicate that the SUR2B subunit and the Kir6.1 subunit should be a potential target for the treatment of migraine, but proof of concept studies are needed to examine this hypothesis.

Conclusion {#Sec14}
==========

Emerging evidence suggests that K~ATP~ channels could be involved in the pathophysiology of migraine. K~ATP~ channels exist in structures which are believed to be linked to the pathophysiology of migraine, including cerebral and meningeal arteries and the trigeminal system \[[@CR19]--[@CR22]\]. It is established that the cAMP signaling pathway and possibly cGMP signaling pathway are involved in the activation of K~ATP~ channels \[[@CR29]--[@CR31]\]. This is interesting in migraine contexts, as the two signaling pathways are likely to be crucial in the development of a migraine attack.

We suggest that the presented clinical and theoretical evidence support further studies of K~ATP~ channel openers in migraine context. Future human studies will help clarify the role of K~ATP~ channels in the pathophysiology of migraine.
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